Ceragenix Pharmaceuticals

Ceragenix Reports 2005 Year-End Financial Results and Business
Genetic Engineering News - Ceragenix Pharmaceuticals, Inc., (OTCBB: CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced financial results for the full-year ended December 31, 2005. "2005 was a year in which we strengthened our

Ceragenix loses almost $13M in 2005
Denver Business Journal - The Denver company (OTCBB: CGXP), which doesn't have any revenue yet, has lost $13.8 million since 2002. During 2004, the company posted a net loss of $825,711. The red ink amounted to a loss of $1.06 per share last year, up from a loss of 7 cents

In-Vitro Data Show Anti-Angiogenenic Activity Of Ceragenins
Medical News Today - Ceragenix Pharmaceuticals, Inc. ( Ceragenix ), a biopharmaceutical company focused on infectious disease and dermatology, today announced that data received from the National Cancer Institute ( NCI ) showed that two of Ceragenix's Ceragenin